Product Overview
Retatrutide + Cagrilintide Research Peptide Blend
High-quality Retatrutide + Cagrilintide for amylin & combination peptides and laboratory analytical research
Retatrutide + Cagrilintide is supplied as a research peptide blend for qualified laboratory research. It is intended for comparative laboratory studies of triple incretin/glucagon receptor signalling and amylin-related pathways, formulation compatibility and analytical separation. Available specifications: 10 mg, 20 mg; 10 vials per box. The exact component ratio and total content must be confirmed on the batch COA before publication. For laboratory research use only. Not for human consumption, clinical use, diagnosis, treatment, compounding or veterinary use.
Synonym(s): Retatrutide and Cagrilintide research blend
Packaging & Availability
Pricing is supplied on request. Select one or more pack sizes to add them to your quote cart.
| Select | SKU | Pack Size | Availability | Price |
|---|---|---|---|---|
| RC10 | 10mg/vial | 10vial/box;MOQ:100boxes or 1000vial | On request | |
| RC20 | 20mg/vial | 10vial/box;MOQ:100boxes or 1000vial | On request |
Product Overview
Retatrutide + Cagrilintide is a two-component research blend intended for comparative laboratory studies of triple incretin/glucagon receptor signalling and amylin-related pathways, formulation compatibility and analytical separation. The material is intended for qualified research organisations, analytical laboratories and product-development teams. It is supplied under batch-controlled conditions, and the final website specification must match the released COA.
Key Features
- Product type: Research Peptide Blend
- Available specifications: 10 mg, 20 mg; 10 vials per box
- Purity / grade: Component identity, ratio and purity must be stated on the batch COA
- Appearance: White to off-white lyophilized powder; confirm against the batch COA
- Documentation: Batch COA; HPLC chromatogram; MS report; SDS and specification sheet where applicable
- Bulk supply and custom labelling are available subject to technical and compliance review
- The component ratio, total content and analytical release method must be shown on the batch COA
Research Applications
Typical non-clinical research use includes amylin & combination peptides, receptor or enzyme assays, peptide or small-molecule characterisation, chromatographic method development, mass-spectrometric confirmation, stability assessment and formulation compatibility studies. Researchers should determine suitability for their own protocol.
Supply & Quality Documentation
Batch-specific quality documentation is available according to the selected grade and order. Technical values shown on the website should be reconciled with the final COA, HPLC and MS results before release.
For laboratory research use only. Not for human consumption, clinical use, diagnosis, treatment, compounding or veterinary use.
Frequently Asked Questions
What is Retatrutide + Cagrilintide?
Retatrutide + Cagrilintide is a two-component research blend intended for comparative laboratory studies of triple incretin/glucagon receptor signalling and amylin-related pathways, formulation compatibility and analytical separation. It is supplied solely for qualified laboratory research.
What specifications are available for Retatrutide + Cagrilintide?
Current catalogue specifications are 10 mg, 20 mg; 10 vials per box. Final availability must be confirmed when requesting a quotation.
How is the component ratio confirmed?
The exact component ratio, individual component content, total content and analytical release method must be stated on the batch COA before the product page is published.
What purity is supplied?
Component identity, ratio and purity must be stated on the batch COA. The batch COA is the controlling quality record.
Which quality documents are available?
Batch COA; HPLC chromatogram; MS report; SDS and specification sheet where applicable. Document availability depends on the selected grade and batch.
How should Retatrutide + Cagrilintide be stored?
Store sealed at −20°C, protected from light and moisture. After reconstitution, follow the batch-specific stability instructions and avoid repeated freeze–thaw cycles.
Is Retatrutide + Cagrilintide intended for human use?
No. It is supplied for laboratory research only and is not intended for human consumption, clinical use, diagnosis, treatment, compounding or veterinary use.
Product Properties
| Product Name | Retatrutide + Cagrilintide |
|---|---|
| Product Type | Research Peptide Blend |
| Main Category | Metabolic Peptides |
| Subcategory | Amylin & Combination Peptides |
| Available Specifications | 10 mg, 20 mg; 10 vials per box |
| Purity / Grade | Component identity, ratio and purity must be stated on the batch COA |
| Appearance | White to off-white lyophilized powder; confirm against the batch COA |
| Storage | Store sealed at −20°C, protected from light and moisture. After reconstitution, follow the batch-specific stability instructions and avoid repeated freeze–thaw cycles. |
| Quality Documents | Batch COA; HPLC chromatogram; MS report; SDS and specification sheet where applicable |
Analytical & Research Scope
Retatrutide + Cagrilintide may be used for comparative laboratory studies of triple incretin/glucagon receptor signalling and amylin-related pathways, formulation compatibility and analytical separation. The purchaser is responsible for validating the material in the intended laboratory method.
Ordering Information
Please specify the required content, batch quantity, target purity, destination country, packaging format and required documents when requesting a quotation.
For laboratory research use only. Not for human consumption, clinical use, diagnosis, treatment, compounding or veterinary use.
- Read the batch-specific Safety Data Sheet before handling.
- Use suitable laboratory gloves, protective clothing and eye protection.
- Avoid inhalation, ingestion and direct contact with skin or eyes.
- Use only in a controlled laboratory environment with appropriate engineering controls.
- Store sealed at −20°C, protected from light and moisture. After reconstitution, follow the batch-specific stability instructions and avoid repeated freeze–thaw cycles.
- Confirm the identity, content and ratio of every component before use in any analytical study.
- Dispose of unused material, containers and solutions in accordance with institutional and local regulations.
No clinical dosing, treatment or consumer-use information is provided.
Quality & Documentation
Safety Data Sheet (SDS), Certificate of Analysis (COA) and specification documents can be supplied with your quotation.